We are a PARENT-LED organization on MISSION to change the lives of ALL struggling Frizzle patients around the world!
We developed a GENE THERAPY DRUG for Frizzle Disease. Learn more HOW YOU CAN HELP fund a future clinical trial!
QUICK INFO & LINKS
-
-
Friends and donors, thank you for caring about Frizzle kids! We have some helpful links to get you the informaiton you need:
-
Welcome! We’re so glad you found us. At Finding Hope for Frizzle (FRRS1L), we believe the knowledge gained through our own treatment development journey should be shared to help others move forward.
We are committed to supporting parent/patient advocacy groups (PAGs) and rare disease organizations working to advance research and develop treatments for their communities.
Explore our resources for practical information, lessons learned, and tools designed to help PAGs at every stage of the treatment development journey—from getting started to moving a potential therapy toward the clinic.
PAG resource page
-
Resources:
-
We have licensed Ben Deverman’s TfR1 CapX technology from Apertura Gene Therapy for our FRRS1L gene therapy program. We look forward to sharing insights that help move science and treatment development forward. Learn more about our desire to collaborate and share about CapX as our program develops.
-
At Finding Hope for Frizzle (FRRS1L), we are proud of what we have accomplished—as an organization, as parents of children living with Frizzle, and as drug developers working to move a treatment from an idea toward patients.
We believe the lessons we have learned along the way can help strengthen the broader rare disease and drug development communities. Our team welcomes opportunities to speak, share our experience, and participate in industry conferences, panels, workshops, meetings, and educational events.
Topics can include parent-led drug development, patient advocacy, treatment development, organizational ownership, partnerships, navigating the development process, and the unique perspective of being both parents and drug developers.
Interested in having a member of our team speak at your event?
Send your speaking request to contact@FRRS1L.org
-
Stay up to date with the latest Finding Hope for Frizzle (FRRS1L) organizational updates, treatment development news, partnerships, and announcements by visiting our Media Page.
For media inquiries, interview requests, or additional information, please contact our team at contact@FRRS1L.org.
WHY THIS MATTERS
CHANGE LIVES and CHANGE the WORLD for ALL NEURO DISEASE.
Finding Hope for Frizzle (FRRS1L) is a parent-led, Colorado registered 501c3 nonprofit organization, dedicated to developing life-changing treatment for children living with FRRS1L (pronounced Frizzle) genetic disease. The organization leads a comprehensive therapeutic development program spanning scientific research, regulatory strategy, manufacturing, clinical development, and patient advocacy, with the mission of bringing an effective gene replacement therapy treatment to patients as quickly as possible while helping advance the future of all neuro disease drug development. The organization has no paid staff and all donated dollars go to directly fund an upcoming FRRS1L clinical trial.
Finding Hope for Frizzle has licensed the new TfR1 CapX capsid technology. The collaboration marks a major milestone not only for families affected by Frizzle disease, but also for the future of gene therapy. The clinical program will utilize the innovative TfR1 CapX capsid, a next-generation AAV delivery platform designed to improve distribution of gene therapies throughout the brain following an intravenous (IV) infusion.
While a trial woud be focused on treating children with Frizzle disease, the implications with this therapeutic capsid extend far beyond a single rare disease. It has the potential to change gene therapy delivery for all neurological disease such as Alzheimer's and Parkinson’s disease. The successful clinical application of TfR1 CapX has the potential to accelerate the development of gene therapies for numerous neurological disorders by demonstrating a more efficient method of delivering genetic medicines throughout the central nervous system. If successful, the knowledge gained through this program could help shape the future of gene therapy for patients around the world. Learn more here.
WE NEED YOUR HELP!
It wasn't always like this for children with FRRS1L gene disorder.
Before the disorder took full effect, parents knew and saw their children to be busy toddlers. FRRS1L is a critical brain encoding gene that affects all cells in the brain. Children with this gene disorder develop, albeit delayed, until age two when they begin having seizural activity that causes regression and total loss of function.